Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Synthesis and Regulation of Thyroid Hormones01:20

Synthesis and Regulation of Thyroid Hormones

6.7K
Low blood levels of the thyroid hormones — triiodothyronine (T3) and thyroxine (T4) — signal the hypothalamus to release the thyrotropin-releasing hormone (TRH). TRH then reaches the pituitary gland and stimulates the release of thyroid-stimulating hormone(TSH) into the bloodstream.
Upon reaching the thyroid gland, TSH stimulates the follicular cells' active uptake of iodide ions from the blood. The ions diffuse to the apical surface of the cells and are oxidized to iodine. The...
6.7K
Cholinergic Antagonists: Therapeutic Uses01:26

Cholinergic Antagonists: Therapeutic Uses

1.2K
Antimuscarinic drugs have various therapeutic applications by inhibiting parasympathetic stimulation in different systems. Here are the key therapeutic uses of antimuscarinics:    
Respiratory Tract: Ipratropium, aclidinium, and tiotropium treat asthma, chronic bronchitis, and chronic obstructive pulmonary disease (COPD). They protect against bronchoconstriction caused by irritants like cigarette smoke, sulfur dioxide, and ozone. They also help reduce nasopharyngeal...
1.2K
Direct-Acting Cholinergic Agonists: Therapeutic Uses01:11

Direct-Acting Cholinergic Agonists: Therapeutic Uses

1.4K
Direct-acting cholinergic agonists have many therapeutic uses in various medical fields. Choline esters, including acetylcholine, have limited clinical utility due to their non-selectivity and short duration of action. Still, acetylcholine and carbachol are applied topically during ophthalmologic surgery to induce miosis. Pilocarpine, a muscarinic and ganglionic stimulator, effectively treats open-angle glaucoma and alleviates xerostomia and dry mouth caused by radiotherapy or Sjögren...
1.4K
The Thyroid Gland01:23

The Thyroid Gland

6.2K
The thyroid gland is a small, butterfly-shaped gland located in the neck and covers the anterior surface of the trachea. The gland has two lateral lobes connected by a thin tissue mass called the isthmus. Internally, each lobe comprises many small spherical structures known as thyroid follicles, surrounded by a network of blood vessels.
The follicles have a central cavity lined by simple cuboidal to squamous epithelial cells called follicular cells. These cells produce the glycoprotein...
6.2K
Therapeutic Drug Monitoring: Overview and Classification01:16

Therapeutic Drug Monitoring: Overview and Classification

157
Therapeutic Drug Monitoring (TDM) is a clinical practice that measures specific drug levels in a patient's blood at designated intervals to ensure the drug concentration stays within a therapeutic range. This monitoring is crucial for optimizing individual dosage regimens, enhancing therapeutic efficacy, and minimizing drug-related toxicity. TDM is vital for drugs with narrow therapeutic windows, significant variability in pharmacokinetics, and a clear correlation between plasma levels and...
157
Myasthenia Gravis: Overview and Treatment01:20

Myasthenia Gravis: Overview and Treatment

2.5K
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
2.5K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

THESIS (Treatment of Hypothyroidism in Europe by Specialists: An International Survey) Questionnaire Survey of Medical Thyroid Specialists in Korea on the Use of Thyroid Hormones in Hypothyroid and Euthyroid Patients.

Endocrinology and metabolism (Seoul, Korea)·2026
Same author

Mild Thyroid Eye Disease-The Most Common yet the Least Studied Presentation of Thyroid Eye Disease.

Thyroid : official journal of the American Thyroid Association·2026
Same author

Post-thyrotoxicosis weight gain: time to stratify and treat?

Nature reviews. Endocrinology·2026
Same author

Use of Thyroid Hormones in Patients with Hypothyroidism and Euthyroidism in the United States: American Association of Clinical Endocrinology International Collaboration with the THESIS Investigators.

AACE endocrinology and diabetes·2026
Same author

PERSPECTIVE: Prioritizing quality of life in the management of hyperthyroidism: an expert clinical perspective.

Endocrine connections·2026
Same author

Weight Gain after Treatment of Hyperthyroidism is Associated with Impairment of Quality of Life.

Thyroid : official journal of the American Thyroid Association·2025

Related Experiment Video

Updated: Dec 10, 2025

Transoral Endoscopic Thyroidectomy Vestibular Approach for Thyroid Lobectomy
05:12

Transoral Endoscopic Thyroidectomy Vestibular Approach for Thyroid Lobectomy

Published on: May 12, 2023

4.4K

New Therapeutic Horizons for Graves' Hyperthyroidism.

Laura C Lane1,2,3, Tim D Cheetham1,3, Petros Perros2

  • 1Translational and Clinical Research Institute, Newcastle University, Newcastle-upon-Tyne, UK.

Endocrine Reviews
|August 27, 2020
PubMed
Summary

Novel therapies offer new hope for Graves' hyperthyroidism patients. Targeted treatments, including biologics and small molecules, aim to restore thyroid balance without lifelong medication or immune disruption.

Keywords:
Graves’ diseasehyperthyroidismimmunomodulationimmunotherapythyroid hormonethyroid-stimulating hormone receptor

More Related Videos

Gasless Endoscopic Thyroidectomy via the Trans-Axillary Approach
05:10

Gasless Endoscopic Thyroidectomy via the Trans-Axillary Approach

Published on: September 15, 2023

1.5K
Minimal Invasive Resection of Large Retrosternal Thyroid Goiter
04:09

Minimal Invasive Resection of Large Retrosternal Thyroid Goiter

Published on: September 20, 2024

645

Related Experiment Videos

Last Updated: Dec 10, 2025

Transoral Endoscopic Thyroidectomy Vestibular Approach for Thyroid Lobectomy
05:12

Transoral Endoscopic Thyroidectomy Vestibular Approach for Thyroid Lobectomy

Published on: May 12, 2023

4.4K
Gasless Endoscopic Thyroidectomy via the Trans-Axillary Approach
05:10

Gasless Endoscopic Thyroidectomy via the Trans-Axillary Approach

Published on: September 15, 2023

1.5K
Minimal Invasive Resection of Large Retrosternal Thyroid Goiter
04:09

Minimal Invasive Resection of Large Retrosternal Thyroid Goiter

Published on: September 20, 2024

645

Area of Science:

  • Endocrinology
  • Immunology
  • Pharmacology

Background:

  • Graves' hyperthyroidism involves autoantibodies stimulating the TSHR, causing excess thyroid hormone secretion.
  • Current treatments (medication, radioiodine, surgery) have limitations and have seen little innovation for 70 years.
  • There's a significant need for more effective and targeted therapies for Graves' disease.

Purpose of the Study:

  • To review recent advances in novel therapeutic approaches for Graves' hyperthyroidism.
  • To summarize the development stages of emerging treatments.
  • To highlight TSHR-specific modalities and their potential clinical impact.

Main Methods:

  • Comprehensive literature review of current and emerging Graves' hyperthyroidism treatments.
  • Analysis of novel therapeutic strategies including biologics, small molecules, and peptide immunomodulation.
  • Focus on TSHR-specific treatments and their immunobiological basis.

Main Results:

  • Several novel therapeutic options are under investigation for Graves' hyperthyroidism.
  • TSHR-specific treatments offer targeted approaches with reduced risk of immune system disruption.
  • Emerging therapies show promise for restoring euthyroidism without long-term treatment needs.

Conclusions:

  • Novel therapeutic strategies are emerging for Graves' hyperthyroidism, addressing limitations of conventional treatments.
  • TSHR-specific therapies represent a significant advancement, offering targeted and potentially curative options.
  • These innovative treatments are nearing clinical translation, providing hope for improved patient outcomes.